Janux Therapeutics (JANX) Depreciation & Amortization (CF) (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $469000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 9.63% year-over-year to $469000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 3.32% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 1.5% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $469000.0, roughly flat from $468000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for JANX reached as high as $541000.0 in Q2 2025 and fell as low as $81000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $432588.2 across 5 years, with a median of $500000.0 in 2023.
• Across the five-year window, Depreciation & Amortization (CF) jumped 822.22% in 2022 and decreased 9.63% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $403000.0 in 2022, then jumped by 31.76% to $531000.0 in 2023, then slipped by 3.58% to $512000.0 in 2024, then slipped by 8.59% to $468000.0 in 2025, then rose by 0.21% to $469000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $469000.0 in Q1 2026, $468000.0 in Q4 2025, and $501000.0 in Q3 2025.